Angiotensin II receptor blocker telmisartan: Effect on blood pressure profile and left ventricular hypertrophy in patients with arterial hypertension

Journal of International Medical Research

Volumn 33, Issue SUPPL. 1, 2005, Pages

  Ivanova, O V ^a   Fomicheva, O A ^a   Sergakova, L M ^a   Chernova, N A ^a   Rogoza, A N ^a   Karpov, Y A ^a  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

Author keywords

Ambulatory blood pressure monitoring; Angiotensin II receptor blocker; Hypertension; Left ventricular hypertrophy; Telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; TELMISARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; OPEN STUDY; OUTCOMES RESEARCH; SYSTOLIC BLOOD PRESSURE; TWO DIMENSIONAL ECHOCARDIOGRAPHY;

EID: 25844512492     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/14732300050330s104     Document Type: Article

References (25)

1. Verdecchia P, Carini G, Circo A. Dovellini E, Giovannini E, Lombardo M, et al: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38: 1829-1835.
2. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90: 1786-1793.
3. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E: Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091-1095.
4. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
5. Mancini GB, Stewart DJ: Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding? Can J Cardiol 2001; 17 (Suppl A): 15A-17A.
6. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000; 52: 11-34.
7. Hollenberg NK, Fisher ND, Price DA: Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 1998; 32: 387-392.
8. Dahlof B, Pennert K, Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
9. Schmieder RE, Martus P, Klingbeil A: Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 1996; 275: 1507-1513.
10. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998; 15: 206-217.
11. Sharpe M, Jarvis B, Goa KL: Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501-1529.
12. Smith DHG, Matzek KM, Kempthorne-Rawson J: Dose response and safety of telmisartan in patients with mild to moderate hypertension. J Clin Pharmacol 2000; 40: 1380-1390.
13. Guidelines Subcommittee: 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17: 151-183.
14. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
15. Devereux RB, Dahlof B, Levy D, Pfeffer MA: Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996; 78: 61-65.
16. Pickering TG, Coats A, Mallion JM, Mancia G, Verdecchia P: Blood pressure monitoring. Task force V: white-coat hypertension. Blood Press Monit 1999; 4: 333-341.
17. Lacourciere Y, Neutel JM, Smith DH: Twenty-four hour blood pressure monitoring to compare efficacy and duration of the ATII antagonist telmisartan to amlodipine. Am J Hypertens 1997; 10: 7A.
18. Meredith PA, Elliott HL: Antihypertensive treatment and trough:peak ratio: general considerations. J Hypertens 1994; 12 (Suppl 8): S79-S83.
19. Zannad F, Matzinger A, Larche J: Trough/peak ratios of once daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633-643.
20. Parati G, Lantelme P: Blood pressure variability, target organ damage and cardiovascular events. J Hypertens 2002; 20: 1725-1729.
21. White WB: Ambulatory blood pressure monitoring: dippers compared with non-dippers. Blood Press Monit 2000; 5 (Suppl 1): S17-S23.
22. Weber MA: The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am J Cardiol 2002; 89: 27A-33A.
23. Lacourciere Y, Tytus R, O'Keefe D, Lenis J, Orchard R, Martin K: Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001; 15: 763-770.
24. Neutel JM, Klein C, Meinicke TW, Schumacher H: Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Am Hypertens 2001; 14 (Suppl 1): A106.
25. Mancia G: Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo. Am J Hypertens 2002; 15 (Supp 1): A54.